Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant btn SARS-CoV-2 S protein (HV69-70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H), His,Avitag™, 25µg  

Recombinant btn SARS-CoV-2 S protein (HV69-70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H), His,Avitag™, 25µg

Recombinant Biotinylated SARS-CoV-2 S protein (HV69-70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) trimer, expressed from human 293 cells (HEK293), His,Avitag™ (MALS verified)

Synonyms: Recombinant, protein, Spike, S protein, Spike glycoprotein, S glycoprotein, COVID-19

More details

SPN-C82E5-200

Availability: within 7 days

2 200,00 €

Background
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant biotinylated SARS-CoV-2 S protein trimer, His,Avitag (SPN-C82E5) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P/ A892P/ A899P/ A942P/ K986P/ V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively. HV69-70del/ Y144del/ N501Y/ A570D/ D614G/ P681H/ T716I/ S982A/ D1118H/ mutations were identified on the spike protein in the SARS-CoV-2 variant (known as B.1.1.7, 20B/501Y.V1 or VOC 202012/01) which emerged in the United Kingdom.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.The protein has a calculated MW of 139.4 kDa. The protein migrates as 160-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Bioactivity
Please refer to product data sheet.

Storage
Avoid repeated freeze-thaw cycles.
-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution

References

  • "Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies" Kumar Verma, Kumar, Singh et al. Biomed Pharmacother (2021) 137, 111356

  • "The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor" Hu, Meng, Zhang et al. Emerg Microbes Infect (2021)

  • "COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment" Munavalli, Guthridge, Knutsen-Larson et al. Arch Dermatol Res (2021)